Satellos Bioscience, a biotechnology company in Canada, has received clearance from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its investigational medicine, forazapadin, in adults living with facioscapulohumeral muscular dystrophy (FSHD). The company has also announced a funding partnership with the FSHD Canada Foundation that could provide up to US$5 million to support the programme.
The trial is expected to begin later in 2026 and will evaluate the investigational therapy in adults living with FSHD.
What is forazapadin?
Forazapadin is an investigational oral medicine designed to support the body’s natural muscle repair and regeneration processes. This approach differs from many other investigational therapies being developed for FSHD that focus on reducing the harmful effects of the DUX4 gene active in people living with FSHD.
Researchers believe that improving the ability of muscle tissue to repair itself could potentially complement other treatment approaches. However, it remains unclear whether enhancing muscle regeneration will lead to improvements in muscle strength and function or quality of life for people living with FSHD.
What will the clinical trial investigate?
The planned study is expected to be a Phase 2, randomised, placebo-controlled clinical trial in adults living with FSHD.
Researchers will investigate safety and tolerability; how forazapadin is processed by the body; whether there are any early signs of benefit; and any other information that may help guide future studies. The results will help determine whether the investigational therapy should advance to later-stage clinical development.
Why is this important for the FSHD community?
There are currently no approved disease-modifying treatments for FSHD. But each new clinical trial expands the range of approaches being explored and helps build understanding of FSHD may be treated in the future.
The announcement is also a reminder of the important role that partnerships between industry, researchers, patient organisations, and the FSHD community can play in advancing research. The investment by FSHD Canada Foundation reflects confidence in continuing research into muscle regeneration as a potential treatment strategy.
Remaining cautiously optimistic
While this announcement is an important milestone, it is not evidence that the investigational therapy works.
Some uncertainties remain. The ability of forazapadin to improve muscle strength, physical function or quality of life remains unknown. Although Satellos is also exploring how it works with people living with Duchenne Muscular Dystrophy (DM), findings from other neuromuscular diseases may not necessarily apply to FSHD.
Next steps
Satellos expects to start the Phase 2 study later in 2026. For now, the FDA decision represents another step forward for FSHD research and adds a new investigational therapy to the growing clinical pipeline. We look forward to hearing updates and sharing them with our community.
Learn more
- Learn more about why trials generally invite people in their country to participate